Business
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
HAYWARD, Calif., May 12, 2026--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences’ common stock through its at-the-market equity offering program (ATM) during the Company’s designated trading window.
About this update from Pulse Biosciences, Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/4f78cd9b45dd746d74c0feb80bb62902"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bdUuh3Ulcn50kpVwy_.sfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/4f78cd9b45dd746d74c0feb80bb62902","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Pqw8pQs0CLW5klUs2KJ.uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/4f78cd9b45dd746d74c0feb80bb62902","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/htABZ6upSKciJUzHgUe_QQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/4f78cd9b45dd746d74c0feb80bb62902","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HAYWARD, Calif., May 12, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, completed purchases of Pulse Biosciences’ common stock through its at-the-market equity offering program (ATM) during the Company’s designated trading window.","length":451,"tagName":"p"},{"type":"text","content":"In total, the Co-Chairmen acquired 675,233 shares of Pulse Biosciences’ common stock for an aggregate purchase price of approximately $13.3 million.","length":148,"tagName":"p"},{"type":"text","content":"About Pulse Biosciences®","length":24,"tagName":"p"},{"type":"text","content":"Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and provi...